ClinicalTrials.gg
CompletedNCT00002320Updated Dec 12, 2005

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

A Phase 3 interventional study of Lamivudine and Zidovudine in HIV Infections, sponsored by Glaxo Wellcome. Completed at 22 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2005-12-12.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
36th of 126
320 · median 154
Phase 3
50 of 132
2 open now
Registered
1st of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is the 36th largest by enrollment of the 126 interventional ones that give a count, is one of 50 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients.

PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.

Read the detailed description

Patients are randomized to one of four treatment arms: 3TC alone, AZT alone, low-dose 3TC plus AZT, or high-dose 3TC plus AZT. Patients receive treatment for 32 weeks, with possible extension to 52 weeks.

PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.

03

Conditions studied

  • HIV Infections

Keywords

  • Drug Therapy, Combination
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Antiviral Agents
  • Zidovudine
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • positivity.
  • 200-500 cells/mm3.
  • AZT naive status (\<= 4 weeks of prior AZT).

Exclusion criteria

Exclusion Criteria

Patients with the following prior condition are excluded:

History of intolerance to AZT.

Prior Medication:

Excluded:

  • More than 4 weeks of prior AZT.
  • Any prior antiretroviral treatment other than AZT.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
Enrollment
320 participants

Interventions

06

Study locations

22 sites
  • Combat Group
    Los Angeles, California 90028, United States
  • San Diego Community Research Group
    San Diego, California 92104, United States
  • Pacific Oaks Med Group
    Sherman Oaks, California 91403, United States
  • Harbor - UCLA Med Ctr
    Torrance, California 90509, United States
  • Infectious Disease Research Institute Inc
    Tampa, Florida 33614, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Chicago Ctr for Clinical Research
    Chicago, Illinois 60607, United States
  • Louisiana Cardiovascular Research Ctr
    New Orleans, Louisiana 70119, United States
  • CRI of New England
    Brookline, Massachusetts 02445, United States
  • Saint Luke's - Roosevelt Hosp Ctr
    New York, New York 10019, United States
  • Univ of North Carolina School of Medicine
    Chapel Hill, North Carolina 275997215, United States
  • Med College of Ohio
    Toledo, Ohio 43699, United States
  • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    Portland, Oregon 97210, United States
  • Mem Hosp of Rhode Island
    Pawtucket, Rhode Island 02860, United States
  • Central Texas Med Foundation
    Austin, Texas 78751, United States
  • Nicholaos Bellos
    Dallas, Texas 75246, United States
  • Richmond AIDS Consortium
    Richmond, Virginia 23219, United States
  • Wisconsin Community - Based Research Consortium
    Milwaukee, Wisconsin 53202, United States
  • Ottawa General Hospital
    Ottawa, Ontario, Canada
  • Toronto Hosp
    Toronto, Ontario, Canada
  • Montreal Gen Hosp
    Montreal, Quebec, Canada
  • Advance Community Health Services Inc
    Santurce, 00908, Puerto Rico
07

References and documents

Publications

  • Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996 Dec;10 Suppl 5:S11-9. doi: 10.1097/00002030-199612005-00003. PubMed 9030391 ↗
  • Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA, Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996 Aug;10(9):975-81. doi: 10.1097/00002030-199610090-00007. PubMed 8853730 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002320
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Dec 12, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 1994. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine

Start the discussion